Medicines Formulary

Medicines A–Z

G

Drug name	NICE TAs	Comments
Ganfort eye drops		Specialist opthalmogist recommendation
Gaviscon infant
Gefitinib tablets	TA192 - Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
Gelatin (Gelaspan)
Gelatin (Geoplasma)
Gelclair sachets		Oncology and haematology only
Gelofusine infusion
Gemcitabine injection	TA116 - Gemcitabine for the treatment of metastatic breast cancer TA25 - Guidance on the use of gemcitabine for the treatment of pancreatic cancer TA285 - Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer TA476 - Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cance	Negative TA. Hospital use only.
Gemeprost
Gemtuzumab ozogamicin	TA545 - Gemtuzumab ozogamicin for untreated acute myeloid leukaemia

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.